Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.
The agency advises patients to confirm that any cell, gene, or tissue therapy they receive is approved by a regulator or authorized for use in a clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback